Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-129248 · Präparat HOS-096703
9 expected, due to nevirapine on dolutegravir exposure is induction) likely similar to or less than that of efavirenz. The recommended dose of dolutegravir is 50 mg twice daily when co-administered with nevirapine. As Triumeq is a fixed dose tablet, an additional 50 mg tablet of dolutegravir should be administered, approximately 12 hours after Triumeq for the duration of the nevirapine co-administration (a separate preparation of dolutegravir is available for this dose adjustment, see section 4.2). Rilpivirine Dolutegravir ↔ No dose adjustment is necessary. AUC ↑ 12% Cmax ↑ 13% Cτ ↑ 22% Rilpivirine ↔ Nucleoside reverse transcriptase inhibitors (NRTIs) Tenofovir Dolutegravir ↔ No dose adjustment is necessary when AUC ↑ 1% Triumeq is combined with nucleoside Cmax ↓ 3% reverse transcript inhibitors. Cτ ↓ 8% Tenofovir ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage d42d449a3e03dd839603176b39b13255ed9f1bbe70196acade3487680c9959c4 · Zeichen 8883–10863 im Abschnitt